Revise Notes Psych Flashcards
Korsakoff dementia
Korsakoff Dementia
Pathophysiology
Thiamine deficiency results in haemorrhage within the mamillary bodies of the thalamus and hypothalamus
Clinical Features
Anterograde amnesia - inability to form new memories
Retrograde amnesia with confabulation
Alcohol Related Disorders
Alcohol withdrawal
Pathophysiology
Alcohol results in the following:
Increased GABA mediated inhibition of the CNS (considered a depressant)
Inhibition of NMDA-type glutamate receptors
Therefore alcohol withdrawal results in
Reduced GABA levels leading to CNS overstimulation (disinhibition)
Increased NMDA-glutamate receptor activation
Clinical features
Symptoms often begin 6-12 hours following last drink and peak at approximately 36 hours
Tremor
Tachycardia
Confusion and agitation
Sweating
Delirium tremens can occur at 48-72 hrs and is characterised by
Coarse tremor
Confusion and delusions
Hallucinations
Management of alcohol withdrawal
CIWA scoring with a benzodiazepine, either
Diazepam
Chlordiazepoxide
Some trusts are now using alcohol
Panic disorder
Panic disorder is a type of anxiety disorder characterised by sudden attacks of panic. These can occur at any time and for no clear reason.
Symptoms/signs include:
Palpitations and tachycardia
N&V
Chest pain
Hyperventilation/ SOB
Paraesthesia
Management - NICE guidance:
NICE advocates a stepwise approach
Step 1: Recognition and diagnosis of panic disorder
Step 2: Management within primary care – either:
Mild to moderate panic disorder:
Low intensity interventions - individual facilitated/non-facilitated self-help
Moderate to severe panic disorder:
CBT or
An antidepressant - SSRI (sertraline)
Nb. In panic disorder, after improvement, continue the antidepressant for a minimum of 6 months before tapering, to reduce the risk of relapse.
Generalised anxiety disorder
Diagnosis of GAD
The DSM-5 criteria for a diagnosis of GAD includes the following symptoms for at least 6 months:
Excessive worry about everyday issues in a manner in which anxiety is disproportionate to risk
At least 3 of the following:
Nervousness/restlessness
Fatigue and tiredness all the time
Poor concentration
Irritability
Muscle tension e.g. in neck and shoulders – this can manifest as tension headaches
Disturbed sleep or insomnia
A validated questionnaire can be used to help identify the presence of these features, including:
The GAD-2 questionnaire
The GAD-7 questionnaire
7 questions scoring 0-3
5 = mild GAD
10 = moderate GAD
15 = severe GAD
Management of Generalised Anxiety Disorder
NICE recommend the following stepwise process in the management of GAD
Step 1: Education and active monitoring
Step 2: Low-intensity psychological intervention
Individual, non-facilitated self help
Individual guided self help
Psychoeducational groups - group therapy based on CBT principles
Step 3: For patients with GAD with marked functional impairment OR GAD which has not responded to steps 1 and 2 - offer high-intensity psychological intervention OR pharmacological intervention
Psychological interventions include
Individual high intensity CBT
Applied relaxation - A therapy which focuses on relaxing mind and muscles in situations that would normally trigger anxiety
Pharmacological management
1st Line: SSRI – Sertraline
2nd line: Alternative SSRI (escitalopram/paroxetine) or SNRI (duloxetine/venlafaxine)
If these are contraindicated consider pregabalin
Step 4: Specialist referral
Note: Current guidance states that if the patient is improving with an antidepressant, it should be continued for at least 12 months to reduce the risk of relapse.
Agoraphobia
An anxiety disorder which is characterised by an irrational fear of open spaces and crowds.
Patients have a phobia of leaving home, for fear of being in situations where there is no immediate safe place to escape to.
Agoraphobia
An anxiety disorder which is characterised by an irrational fear of open spaces and crowds.
Patients have a phobia of leaving home, for fear of being in situations where there is no immediate safe place to escape to.
Alcohol Related Disorders
Alcohol withdrawal
Pathophysiology
Alcohol results in the following:
Increased GABA mediated inhibition of the CNS (considered a depressant)
Inhibition of NMDA-type glutamate receptors
Therefore alcohol withdrawal results in
Reduced GABA levels leading to CNS overstimulation (disinhibition)
Increased NMDA-glutamate receptor activation
Clinical features
Symptoms often begin 6-12 hours following last drink and peak at approximately 36 hours
Tremor
Tachycardia
Confusion and agitation
Sweating
Delirium tremens can occur at 48-72 hrs and is characterised by
Coarse tremor
Confusion and delusions
Hallucinations
Management of alcohol withdrawal
CIWA scoring with a benzodiazepine, either
Diazepam
Chlordiazepoxide
Some trusts are now using alcohol
Korsakoff Dementia
Pathophysiology
Thiamine deficiency results in haemorrhage within the mamillary bodies of the thalamus and hypothalamus
Clinical Features
Anterograde amnesia - inability to form new memories
Retrograde amnesia with confabulation
nxiety & Panic Disorder
Generalised anxiety disorder
Diagnosis of GAD
The DSM-5 criteria for a diagnosis of GAD includes the following symptoms for at least 6 months:
Excessive worry about everyday issues in a manner in which anxiety is disproportionate to risk
At least 3 of the following:
Nervousness/restlessness
Fatigue and tiredness all the time
Poor concentration
Irritability
Muscle tension e.g. in neck and shoulders – this can manifest as tension headaches
Disturbed sleep or insomnia
A validated questionnaire can be used to help identify the presence of these features, including:
The GAD-2 questionnaire
The GAD-7 questionnaire
7 questions scoring 0-3
5 = mild GAD
10 = moderate GAD
15 = severe GAD
Management of Generalised Anxiety Disorder
NICE recommend the following stepwise process in the management of GAD
Step 1: Education and active monitoring
Step 2: Low-intensity psychological intervention
Individual, non-facilitated self help
Individual guided self help
Psychoeducational groups - group therapy based on CBT principles
Step 3: For patients with GAD with marked functional impairment
OR GAD which has not responded to steps 1 and 2
- offer high-intensity psychological intervention OR pharmacological intervention
Psychological interventions include
Individual high intensity CBT
Applied relaxation - A therapy which focuses on relaxing mind and muscles in situations that would normally trigger anxiety
Pharmacological management
1st Line: SSRI – Sertraline
2nd line: Alternative SSRI (escitalopram/paroxetine) or SNRI (duloxetine/venlafaxine)
If these are contraindicated consider pregabalin
Step 4: Specialist referral
Note: Current guidance states that if the patient is improving with an antidepressant, it should be continued for at least 12 months to reduce the risk of relapse.
Panic disorder
Panic disorder is a type of anxiety disorder characterised by sudden attacks of panic. These can occur at any time and for no clear reason. Symptoms/signs include:
Palpitations and tachycardia
N&V
Chest pain
Hyperventilation/ SOB
Paraesthesia
Management - NICE guidance:
NICE advocates a stepwise approach
Step 1: Recognition and diagnosis of panic disorder
Step 2: Management within primary care – either:
Mild to moderate panic disorder:
Low intensity interventions - individual facilitated/non-facilitated self-help
Moderate to severe panic disorder:
CBT or
An antidepressant - SSRI (sertraline)
Nb. In panic disorder, after improvement,
continue the antidepressant for a minimum of 6 months before tapering, to reduce the risk of relapse.
Agoraphobia
Agoraphobia
An anxiety disorder which is characterised by an irrational fear of open spaces and crowds. Patients have a phobia of leaving home, for fear of being in situations where there is no immediate safe place to escape to.
Suicide: Risk stratification
There is increased risk of attempted and completed suicide with:
Male sex
History of deliberate self harm (DSH)
History of alcohol/drug misuse
Background of mental health illness
History of chronic disease
Increasing age
Unemployment, lack of social network/isolation
Living alone, loneliness
Single/widowed or divorced
Electroconvulsive therapy (ECT)
Considered in cases of severe depression which is REFRACTORY to medical management
Absolute contraindication: Raised intracranial pressure
Adverse effects
Short term: Headache, short term memory loss, Arrhythmias
Long term: Impaired memory
Seasonal Affective Disorder
Depressive symptoms occurring within the winter months
Management is the same as ‘typical’ depression (i.e. CBT and SSRIs if required etc.)
Depression in elderly patients
Clinical features
Elderly patients are less likely to complain of depressed mood and may have atypical symptoms such as agitation or insomnia.
They may also be worried about memory loss and concerned about dementia -
the memory loss they experience is global (whereas dementia affects more recent memories)
Biological symptoms – weight loss, sleep disturbance
Management
1st Line: SSRI
Depression
Depression
Depression is the most common mental health disorder in the UK and is characterised by low mood, fatigue and feelings of worthlessness.
Diagnosis of depression
Depression is diagnosed using the DSM-5 criteria
A diagnosis of depression can be made
if 5 or more of the following core symptoms are present for 2 weeks or more:
Depressed mood most of the time
Anhedonia - diminished enjoyment or pleasure in most activities
Weight change - Unintentional weight loss or weight gain
Slow thought or movement
Fatigue
Feelings of worthlessness
Difficulty concentrating or making decisions
Thoughts of death or suicidal ideation
Other symptoms include:
Sleep disturbance – decreased or increased
Abnormal appetite
Irritability
Classification of severity:
<5 symptoms = subthreshold depression
5-6 symptoms with minor functional impairment = mild depression
Moderate depression = somewhere in between mild/severe
Most/all of the above symptoms = severe depression, severe functional impairment
Assessment of depression
PHQ9 – assessment of symptoms over the last 2 weeks – 9 questions scoring 1-3 each
NICE classifies depression according to severity, using the PHQ-9 scale:
Less severe depression
A score of less than 16 on the PHQ-9 scale
Encompasses subthreshold and mild depression
More severe depression
A score of 16 or more on the PHQ-9 scale
Encompasses moderate and severe depression
Management of depression
Less severe depression and does not want treatment/symptoms improving
Offer active monitoring and review in 2-4 weeks
Less severe depression and wants treatment
1st line: Offer guided self-help (e.g. CBT)
Do not routinely offer an
antidepressant. If the patient wants drug treatment, commence SSRI.
More severe depression
Offer any of the following as 1st line treatment options, depending on patient’s wishes:
Individual CBT
Antidepressant medication
Individual behavioural activation
Group exercise
If the patients wants to start treatment with an antidepressant - offer SSRI or SNRI 1st line
Review in 2-4 weeks
Choosing an antidepressant
First-line: SSRIs – Sertraline or citalopram preferred for most due to safety and tolerability.
Caution: Citalopram may prolong QTc, requiring ECG monitoring
SSRIs such as sertraline are also preferred in the context of physical health conditions, due to lower drug interaction risk.
Sertraline has been shown to be safe in patients with IHD such as unstable angina/recent MI
Fluoxetine is the preferred antidepressant for depression in children and young people.